Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Bamias A, Bamia C, Karadimou A, Soupos N, Zagouri F, Rodolakis A, Haidopoulos D, Vlahos G, Thomakos N, Antsaklis A, Dimopoulos MA.
Oncology. 2011;81(5-6):365-71. Epub 2012 Jan 13.
Related citations
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
Bruzzone M, Centurioni MG, Giglione P, Gualco M, Merlo DF, Miglietta L, Cosso M, Giannelli F, Cristoforoni P, Ferrarini M.
Oncology. 2011;80(3-4):238-46. Epub 2011 Jul 5.
Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.
Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, Hilpert F, Arnold N, Maass N, Meinhold-Heerlein I, Wagner W.
Oncology. 2011;80(1-2):12-20. Epub 2011 May 16.
Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.
Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardigno D, Putignano G, Selvaggi LE.
Oncology. 2011;80(1-2):102-6. Epub 2011 Jun 14. Review.
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A, Mendiola C, Pérez-Ruiz E, Rodríguez-Sánchez CA, Jurado JM, Alonso-Carrión L, Ghanem I, de Velasco G, Quero-Blanco C, Alba E.
Oncology. 2010;79(1-2):98-104. Epub 2010 Nov 15.
CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial.
Markman M, Petersen J, Belland A, Burg K.
Oncology. 2010;78(1):1-2. Epub 2010 Mar 6. No abstract available.
Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study.
Benedetti Panici P, Palaia I, Graziano M, Bellati F, Manci N, Angioli R.
Oncology. 2010;78(1):20-5. Epub 2010 Feb 24.
Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study.
Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS.
Oncology. 2009;77(6):395-9. Epub 2010 Feb 2.
VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice.
Bai Y, Deng H, Yang Y, Zhao X, Wei Y, Xie G, Li Z, Chen X, Chen L, Wang Y, Su D, Qian Z, Zhong Q, Luo H, Yi T.
Oncology. 2009;77(6):385-94. Epub 2010 Feb 2.
Paraneoplastic neurological syndromes and the role of PET imaging.
Sioka C, Fotopoulos A, Kyritsis AP.
Oncology. 2010;78(2):150-6. Epub 2010 Apr 13. Review.
Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV 3rd, Markman M.
Oncology. 2010;78(5-6):389-93. Epub 2010 Aug 27.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on